Search results for "adrenal"

showing 10 items of 416 documents

A Case of Stage IV Chromophobe Renal Cell Carcinoma Treated with the Oncolytic ECHO-7 Virus, Rigvir®

2019

Patient: Male, 59 Final Diagnosis: Chromophobe renal cell carcinoma, stage IV Symptoms: Discomfort in the right hypochondrium Medication: Oncolytic virus Rigvir Clinical Procedure: Nephro-adrenalectomy Specialty: Oncology Objective: Unusual or unexpected effect of treatment Background: Renal cell carcinoma is the most commonly diagnosed primary malignant tumor of the kidney in adults, and includes the variant of chromophobe renal cell carcinoma. Despite new targeted therapies that improve progression-free survival (PFS) and overall survival (OS) for early-stage renal cell carcinoma, the 5-year survival for patients with stage IV renal cell carcinoma remains below 10%, and the 50% OS is less…

Malemedicine.medical_specialtymedicine.medical_treatmentChromophobe Renal Cell CarcinomaAdrenal Gland NeoplasmsUrology030204 cardiovascular system & hematologyNephrectomyVirus03 medical and health sciences0302 clinical medicineRenal cell carcinomamedicineCarcinomaHumansCarcinoma Renal CellOncolytic VirotherapyKidneybusiness.industryAdrenalectomyAdrenalectomyArticlesGeneral MedicineMiddle Agedmedicine.diseaseKidney NeoplasmsNephrectomyEnterovirus B HumanOncolytic virusOncolytic Virusesmedicine.anatomical_structure030220 oncology & carcinogenesisbusinessAmerican Journal of Case Reports
researchProduct

Impact of Chemical Endocrine Disruptors and Hormone Modulators on the Endocrine System

2022

There is growing concern regarding the health and safety issues of endocrine-disrupting chemicals (EDCs). Long-term exposure to EDCs has alarming adverse health effects through both hormone-direct and hormone-indirect pathways. Non-chemical agents, including physical agents such as artificial light, radiation, temperature, and stress exposure, are currently poorly investigated, even though they can seriously affect the endocrine system, by modulation of hormonal action. Several mechanisms have been suggested to explain the interference of EDCs with hormonal activity. However, difficulty in quantifying the exposure, low standardization of studies, and the presence of confounding factors do n…

Malephthalatephysical agentsbeta-cellEndocrine SystemtestisEndocrine Disruptorsthyroid.CatalysisthyroidInorganic ChemistrybisphenolHumansparathyroidPhysical and Theoretical ChemistryMolecular BiologySpectroscopyphthalatesV.Organic ChemistryGeneral MedicineHormonestestiComputer Science Applicationsphysical agentadrenalFemaleovary
researchProduct

Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice

2015

International audience; Objective. The aim of this study was to evaluate the impact of introducing tocilizumab (TCZ) as co-therapy with CS in patients with RA.Methods. This study was an open, observational, retrospective multicentre study. RA patients treated with oral CS for >3 months who started treatment with TCZ between December 2009 and June 2011 in five centres were included. Variables included demographic data, disease history, co-treatments, disease activity and dose of CS at inclusion and at weeks 4, 8, 12 and 24. The evolution of disease activity and of the dose of CS (analysis of variance with repeated measures) were analysed, searching for factors correlated with changes in the …

Malerheumatoid arthritisGastroenterologycorticosteroidsArthritis Rheumatoidchemistry.chemical_compoundPrednisoneAdrenal Cortex HormonesPharmacology (medical)risksystemic glucocorticoid therapytreatmentfactor-alpha inhibitorsMiddle Aged3. Good healthClinical PracticeTreatment Outcome[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemRheumatoid arthritisAntirheumatic AgentsCorticosteroidDrug Therapy CombinationFemaleAnalysis of variancemanagementmedicine.drugAdultmedicine.medical_specialtymedicine.drug_classAntibodies Monoclonal Humanizeddiseases[ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemtocilizumabTocilizumabRheumatology[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/MedicationInternal medicinemedicineHumansIn patientbiologicsGlucocorticoidsAgedRetrospective Studiesbusiness.industry[ SDV.SP.MED ] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationRepeated measures designeular recommendationsmedicine.diseaseEndocrinologychemistryPrednisonebusiness
researchProduct

Hyaluronic Acid-Based Micelles as Ocular Platform to Modulate the Loading, Release, and Corneal Permeation of Corticosteroids

2017

The aim of this work is to prepare hyaluronic acid-based micelles as a platform to load corticosteroid drugs and to improve their corneal permeation after administration on the ocular surface. Three amphiphilic derivatives of hyaluronic acid (HA) are synthesized using different amounts of hexadecylamine (C16 -NH2 ). HAC16 a, HAC16 b, and HAC16 c derivatives are able to form micelles by the cosolvent evaporation method and to entrap corticosteroids (dexamethasone, triamcinolone, triamcinolone acetonide). HAC16 a and HAC16 b micelles show the best results in terms of drug loading and particle size. They are also able to improve drug release compared to free drug solution or suspension. In add…

Materials Chemistry2506 Metals and AlloysTriamcinolone acetonidePolymers and PlasticsAdministration Ophthalmic02 engineering and technologyTriamcinolone01 natural sciencesMicelleDexamethasoneCorneachemistry.chemical_compoundDrug Delivery SystemsAdrenal Cortex HormonesHyaluronic acidMaterials ChemistryCorticosteroidAminesCells CulturedMicellesDrug CarriersChemistryPermeation021001 nanoscience & nanotechnology0210 nano-technologyDrug carriermedicine.drugBiotechnologyTranscorneal enhancerHyaluronic acidBioengineering010402 general chemistryPermeabilityBiomaterialsPolymeric micelleAmphiphilemedicineMucoadhesionAnimalsHumansGlucocorticoidsPolymers and PlasticOcular administrationBiomaterialHydrocarbons0104 chemical sciencesDrug LiberationSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoBiophysicsCattleEx vivo
researchProduct

Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study

2020

Abstract Background The role of the gut microbiota in Crohn’s disease (CD) is established and fecal microbiota transplantation (FMT) is an attractive therapeutic strategy. No randomized controlled clinical trial results are available. We performed a randomized, single-blind, sham-controlled pilot trial of FMT in adults with colonic or ileo-colonic CD. Method Patients enrolled while in flare received oral corticosteroid. Once in clinical remission, patients were randomized to receive either FMT or sham transplantation during a colonoscopy. Corticosteroids were tapered and a second colonoscopy was performed at week 6. The primary endpoint was the implantation of the donor microbiota at week 6…

Microbiology (medical)AdultMaleCrohn’s diseasemedicine.medical_specialtymedicine.drug_class[SDV]Life Sciences [q-bio]ColonoscopyPilot ProjectsGut floraMicrobiologyGastroenterologySeverity of Illness Indexlcsh:Microbial ecologylaw.inventionFecal microbiota transplantation03 medical and health sciencesFeces0302 clinical medicineRandomized controlled trialCrohn DiseaselawAdrenal Cortex HormonesInternal medicinemedicineClinical endpointHumansSingle-Blind Method030304 developmental biology0303 health sciencesCrohn's diseasebiologymedicine.diagnostic_testMicrobiotaResearchRemission Inductionbiology.organism_classificationmedicine.disease3. Good healthClinical trialTransplantationCrohn's diseaseTreatment OutcomeResearch DesignRandomized controlled trialCorticosteroidlcsh:QR100-130030211 gastroenterology & hepatologyFemaleMicrobiome
researchProduct

Adrenal myelolipoma associated with adenoma

2004

The association of an adrenal myelolipoma with a non-functioning adenoma is very rare. Herein, we report on such a case in an asymptomatic 64-year-old woman. To the best of our knowledge, there is only one other case of non-functioning adrenocortical adenoma associated with myelolipoma in the same gland. Furthermore, only two other adenomas (mineral corticoids and corticosteroid producing tumors) associated with myelolipomas have been reported, and both myelolipomas were less than 1 cm in size. In conclusion, the 8.5 cm myelolipoma in our case is the largest compared with the three previously reported ones.

MyelolipomaAdenomamedicine.medical_specialtyPathologyAdenomamedicine.drug_classUrologymedicine.medical_treatmentAdrenal Gland NeoplasmsAdrenal neoplasmAsymptomaticadenoma adrenal neoplasms adrenalectomy myelolipoma.Adrenocortical adenomaMyelolipomaInternal medicinemedicineHumansAdrenal myelolipomabusiness.industryAdrenalectomyAdrenalectomyMiddle Agedmedicine.diseaseEndocrinologyCorticosteroidFemalemedicine.symptombusiness
researchProduct

Zur Frage des pl�tzlichen Todes beim sogenannten Myelolipom der Nebennieren

1967

Es wird uber ein doppelseitiges sog. Myelolipom der Nebennieren bei einer 54jahrigen Frau berichtet, das wahrscheinlich uber ein allgemeines Schocksyndrom zum plotzlichen Tode fuhrte.

MyelolipomaGynecologymedicine.medical_specialtymedicine.anatomical_structureEndocrinologyAdrenal glandInternal medicinemedicinemedicine.diseasePsychologySudden deathPathology and Forensic MedicineDeutsche Zeitschrift f�r die Gesamte Gerichtliche Medizin
researchProduct

Open Radical Nephrectomy: 35 Years of Experience at the “Luciano Giuliani” Urological Department of the University of Genoa

2006

Objective: Radical nephrectomy remains the gold standard for surgically resectable kidney neoplasms > 4 cm and, in selected cases, also in presence of metastatic disease. We reviewed the records of the patients having surgery at the University of Genoa in the last 35 yr. Methods: We have retrospectively assessed all the radical nephrectomies performed between 1970 and 2005. Among tumours of the kidney subjected to surgical treatment during this period, we found 1105 cases of histologically proven renal cell carcinoma (RCC), 965 of which had records available for the study. The number of cases per year, symptoms at diagnosis, surgical strategy, staging of the tumour, and survival were rev…

Nephrologycancer incidencemedicine.medical_treatmentkidney carcinomamorbiditysepsisRenal cell carcinomacancer diagnosiscancer mortalitynephrectomypostoperative complicationMyocardial infarctioncancer survivaldisease free survivalcancer diagnosiadrenalectomy; article; cancer diagnosis; cancer incidence; cancer mortality; cancer size; cancer staging; cancer surgery; cancer survival; disease free survival; heart infarction; human; kidney carcinoma; lung embolism; lymphadenectomy; metastasis; morbidity; nephrectomy; partial nephrectomy; postoperative complication; priority journal; sepsis; spleen injury; splenectomy; surgical technique; thrombectomyRadical nephrectomyIncidence (epidemiology)articleadrenalectomyRenal cell carcinomaNephrectomypriority journalthrombectomysepsicancer surgerylung embolismmedicine.medical_specialtypartial nephrectomyUrologyheart infarctionsurgical techniquesplenectomyInternal medicinemedicineCarcinomametastasishumanbusiness.industrycancer stagingmedicine.diseaseSurgeryspleen injurycancer sizelymphadenectomySurgerymetastasibusinessKidney cancerKidney diseaseEuropean Urology Supplements
researchProduct

Neuronal populations mediating the effects of endocannabinoids on stress and emotionality

2011

An adequate emotional response to stress is essential for survival and requires the fine-tuned regulation of several distinct neuronal circuits. Therefore, a precise control of these circuits is necessary to prevent behavioral imbalances. During the last decade, numerous investigations have evidenced that the endocannabinoid (eCB) system is able to crucially control stress coping. Its central component, the cannabinoid type 1 receptor (CB1 receptor), is located at the presynapse, where it is able to attenuate neurotransmitter release after its activation by postsynaptically produced and released eCBs. To date, the eCB system has been found to control the neurotransmitter release from severa…

NeuronsHypothalamo-Hypophyseal SystemGeneral NeuroscienceEmotionsGlutamate receptorPituitary-Adrenal SystemContext (language use)Endocannabinoid systemAmygdalaPresynapsemedicine.anatomical_structureReceptor Cannabinoid CB1nervous systemStress PhysiologicalCannabinoid Receptor ModulatorsSynapsesmedicineAnimalsLocus coeruleusPremovement neuronal activityPsychologyPrefrontal cortexNeuroscienceStress PsychologicalEndocannabinoidsNeuroscience
researchProduct

Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions

2018

IF 0.795 (2017); International audience; The present final consensus statement of the French Society of Endocrinology lays out the assessments that are to be systematically performed before and during anticancer treatment by immunotherapy, tyrosine kinase inhibitors or mTOR inhibitors, even without onset of any endocrinopathy. It also discusses the CTCAE adverse event grading system in oncology and the difficulty of implementing it for endocrine side-effects of these anticancer treatments. Notably, this is why certain treatment steps applied in other side-effects (e.g., high-dose corticosteroids, contraindications to immunotherapy, etc.) need to be discussed before implementation for endocr…

Oncologymedicine.medical_specialtyConsensusEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAntineoplastic Agents030209 endocrinology & metabolism[SDV.CAN]Life Sciences [q-bio]/CancerEndocrine System Diseases03 medical and health sciences0302 clinical medicineEndocrinologyDysthyroidismNeoplasmsInternal medicineAnimalsHumansMedicineEndocrine systemHypophysitisAdverse effectMTOR inhibitorsTyrosine kinase inhibitorsAdrenal failurebusiness.industryDiabetesGeneral MedicineImmunotherapy[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismDiscovery and development of mTOR inhibitors3. Good healthDyslipidemiaAnticancer treatment030220 oncology & carcinogenesisAdrenal failureImmunotherapybusiness
researchProduct